Related Experiment Video
Updated: Jan 20, 2026

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Consolidation Chemotherapy After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: 7-Year Follow-Up
Sojin Kim1, Moon Ki Choi2, Dae Yong Kim2
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Purpose:
Total neoadjuvant therapy has become the standard treatment for locally advanced rectal cancer. However, the optimal sequence and duration of treatment remain unclear. Hence, the long-term follow-up results from our previous randomized phase 2 trial on consolidation chemotherapy, which demonstrated improved short-term pathologic outcomes, could provide valuable clinical evidence supporting total neoadjuvant therapy.
Methods And Materials:
The KCSG CO 14-03 trial is a multicenter, randomized trial involving patients with preoperative cT3-4NxM0 locally advanced rectal cancer. Patients were randomized into 2 arms: (1) preoperative chemoradiation therapy of 50 to 50.4 Gy/25-28 fractions with capecitabine (arm A) and (2) consolidation chemotherapy with 2 capecitabine and oxaliplatin cycles after chemoradiation therapy (arm B). Postoperative adjuvant chemotherapy was administered based on ypStage (ypStage 0-II: capecitabine; III: capecitabine and oxaliplatin) in both arms. The secondary endpoints of this study were disease-free survival (DFS), relapse-free survival, overall survival (OS), cumulative locoregional recurrence rate, long-term safety, and quality of life at 7 years.
Results:
A total of 110 patients were enrolled between June 2014 and March 2016. DFS at 7 years was 61.2% and 75.6% in arms A and B, respectively (hazard ratio, 0.59; 95% CI, 0.28-1.21; P = .148). OS at 7 years was 78.9% and 83.2% in arms A and B, respectively (hazard ratio, 0.75; 95% CI, 0.27-2.08; P = .587). The 7-year cumulative locoregional recurrence and distant recurrence after total mesorectal excision were 6.1% and 29.9% in arm A and 4.0% and 21.8% in arm B, respectively. Drops in the Functional Assessment of Cancer Therapy for patients with Colorectal Cancer total, physical well-being, and functional well-being scores after preoperative treatment were significantly larger in arm B than in arm A. However, no significant change in Functional Assessment of Cancer Therapy for patients with Colorectal Cancer scores was observed between the 2 arms after surgery.
Conclusions:
DFS and OS did not differ significantly between the 2 arms, but there was a numerical improvement in 7-year DFS with consolidation chemotherapy. Quality of life deteriorated significantly with consolidation chemotherapy before surgery, but the difference disappeared after surgery.
More Related Videos
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
Published on: September 16, 2012
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Related Concept Videos
12:45Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
14:45Enumeration of Major Peripheral Blood Leukocyte Populations for Multicenter Clinical Trials Using a Whole Blood Phenotyping Assay
03:55Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:26Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain
Male Rectal Exam
While its usefulness in cancer screening is debated, the male rectal examination remains an important part of the physical exam. The exam is indicated in selected patients with lower urinary tract symptoms, urinary and/or fecal incontinence or retention, back pain, anorectal symptoms, abdominal complaints, trauma patients, unexplained anemia, weight loss, or bone pain. There are no absolute...
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer